Abstract
In this article, the characteristics of onset, symptoms and outcome of first-episode schizophrenia are described. The guidance from the National Institute for Clinical Excellence, to consider atypical antipsychotics as first-line agents for the treatment of first-episode schizophrenia because of a reduced incidence of extrapyramidal symptoms with these agents, is discussed. The propensity for atypical antipsychotics to induce extrapyramidal symptoms is reviewed.
| Original language | English |
|---|---|
| Pages (from-to) | 405-408 |
| Number of pages | 4 |
| Journal | Pharmaceutical Journal |
| Volume | 270 |
| Issue number | 7241 |
| Publication status | Published - 22 Mar 2003 |